The HCPLive Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for C difficile, IBS and IBD, Crohn's disease, and more.
October 27th 2024
New late-breaking ACG 2024 data supports AIMS65 as a risk factor tool for patients undergoing anticoagulant reversal.
Black Patients Receive Less C Diff Tests Despite Similar Positivity Rates to White Patients
November 27th 2023A retrospective cohort study of inpatient encounters from 3 hospitals in the Duke University Health System showed greater rates of testing among White patients compared to Black and NWNB patients.
Study Identifies Predictors of Fibromyalgia, Chronic Fatigue in IBS Patients
October 31st 2023A retrospective analysis of data from the US National Inpatient Sample revealed the prevalence of fibromyalgia and chronic fatigue syndrome was significantly increased in patients with IBS compared to those without IBS.
Guselkumab Leads to Rapid Ulcerative Colitis Symptom Improvement
Induction treatment with guselkumab resulted in a rapid onset of efficacy, beginning at week 1 and increasing over time to week 12, for patients with refractory moderately to severely active ulcerative colitis.
Delphi Consensus Outlines Anti-TNF Introduction, Monitoring Guidelines for Patients with IBD
October 24th 2023Experts recommended the early use of anti-TNF therapy for patients with ulcerative colitis and Crohn disease, offering further input regarding the introduction, optimization, and maintenance of the treatment for patients with IBD.
Study Finds Infliximab Biosimilar Switch Is Safe, Effective for Patients with IBD
October 24th 2023Switching from biosimilar CT-P13 to SB2 is safe and effective, according to new research. The patients in the study had no significant changes in their psychometric assessments during the 12 month follow up.
MACE, VTE Risk Not Increased by Advanced Therapies for Inflammatory Bowel Disease
Advanced therapies for inflammatory bowel disease, namely small molecules and biologic therapies, did not increase the risk of a major adverse cardiovascular event or venous thromboembolism.